Leukemia cutis and all-trans retinoic acid–induced myocarditis in acute promyelocytic leukemia
Acute promyelocytic leukemia (APL) is frequently curable in the modern era using the chemotherapy-free regimen of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). However, rare disease manifestations and treatment complications may threaten these outcomes by requiring intensification or abbreviation of therapy. We present a unique case of a 36-year-old male with newly diagnosed low-risk APL with biopsy-confirmed leukemia cutis and isolated ATRA-associated myocarditis during induction therapy. Both APL leukemia cutis and ATRA-associated myocarditis are exceedingly rare, with each having less than 50 published cases to date. This report offers a comprehensive review of the literature, underscoring the importance of a comprehensive diagnostic evaluation and individualized care to ensure outstanding long-term outcomes for patients with APL.
Authors
- Sarah Profitt (ORCID: https://orcid.org/0000-0002-2705-7512)
- Justin T. Kelley (ORCID: https://orcid.org/0000-0002-7954-5913)
- Anna K. Dewan (ORCID: https://orcid.org/0000-0001-5777-2878)
- Somedeb Ball (ORCID: https://orcid.org/0000-0002-1754-1204)
- Kian J. Rahbari (ORCID: https://orcid.org/0000-0002-6119-3569)
- Kateryna Fedorov (ORCID: https://orcid.org/0009-0004-8876-8926)
- Katie O'connell
- Ashwin Kishtagari
- Parth C. Patel
- Kathryn E. Kennedy
- Erica E. Mittlebeeler
- Sanjay R. Mohan
Institutions
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- Clinical Hematology International
- Published
- 2026-03-26
- DOI
- https://doi.org/10.46989/001c.158170
- Primary Topic
- Retinoids in leukemia and cellular processes
- Type
- article
- Field-Weighted Citation Impact
- 0.00